The safety of rosuvastatin in comparison with other statins in over 25 000 statin users in the Saskatchewan Healh Databases

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 10, 2008, Pages 953-961

  Rodríguez, Luis Alberto García ^a   González Pérez, Antonio ^a   Stang, Mary Rose ^b   Wallander, Mari Ann ^c,d   Johanson, Saga ^c,e  

^a Department of Pharmacoepidemiology   (Spain)

^b Saskatchewan Ministry of Environment   (Canada)

^c ASTRAZENECA R AND D   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Pharmacoepidemiology; Rosuvastatin; Safety; Statin

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CANADA; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LIVER FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOPATHY; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PYRIMIDINES; RHABDOMYOLYSIS; SASKATCHEWAN; SULFONAMIDES; YOUNG ADULT;

EID: 57649162585     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1602     Document Type: Article

References (15)

1. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610. DOI: 10.1016/S0195
2. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790. DOI: 10.1016/S0140
3. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial). Am J Cardiol 2003; 92: 152-160. DOI: 10.1016/S0002
4. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-698.
5. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107: 433-443. DOI: 10.1016/j.amjcard.2004.06.049
6. Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Hering RM. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study. Pharmacoepidemiol Drug Saf 2006; 15: 435-443. DOI: 10.1002/pds.1278
7. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2006; 15: 444-453. DOI: 10.1002/pds.1281
8. Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe1997-2003. Br J Clin Pharmacol 2005; 60: 543-551. DOI: 10.1111/j.1365-2125.2005.02478.x
9. Johansson S, Ming EE, Wallander MA, et al. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. Pharmacoepidemiol Drug Saf 2006; 15: 454-461. DOI: 10.1002/ pds.1260
10. Downey W, Stang M, Beck P, OseiW, Nichol J. Health services databases in Saskatchewan. In Pharmacoepidemiology (4th edn), Strom BL (ed.). John Wiley & Sons: Chichester, West Sussex, UK, 2005; 295-310.
11. Epstein M. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2005; 14: 589-595. DOI: 10.1002/ pds.1082
12. Neutel CI, Morrison H, Campbell NR, de Groh M. Statin use in Canadians: trends, determinants and persistence. Can J Public Health 2007; 98: 412-416.
13. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; 97: 61C-68C. DOI: 10.1016/j.amjcard.2005. 12.011
14. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94: 882-888. DOI: 10.1016/ amjcard.2004.06.09
15. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002; 33: 2337-2341. DOI: 10.1161/ 01.str.0000034125. 94759.41